TL;DR - Palantir reports Q2 2026 tonight after market close (5 PM ET webcast) - Revenue consensus: USD1.812B (+80-85% YoY); company guidance was USD1.797-1.801B - Adj. EPS consensus: USD0.34-0.35 (Q2 2025 actual: USD0.16; +118% YoY) - Eight consecutive earnings beats; Q1 2026 actual revenue USD1.600B (+85% YoY) - Stock at USD123 (-40% from peak, -30% YTD); median analyst target USD200 (+63% upside) - New risk: NHS England reprimanded July 29 for inaccurate Palantir patient data disclosure
Part A: What's on the Table Tonight
Palantir Technologies (NASDAQ: PLTR) will release its Q2 2026 financial results on August 3, 2026, after the U.S. market close, followed by a shareholder Q&A webcast at 5:00 PM ET.
Q2 2026 Consensus vs. Company Guidance
| Metric | Street Consensus | Company Guidance (from Q1) |
|---|---|---|
| Revenue | USD1.812B | USD1.797-1.801B |
| Adj. Income from Ops | ~USD1.065B | USD1.063-1.067B |
| Adj. EPS | USD0.34-0.35 | — |
| Revenue Growth (YoY) | ~80-85% | ~79% (implied) |
The consensus revenue estimate of USD1.812B sits above the company's own guidance midpoint of USD1.799B — consistent with Palantir's track record of conservative guidance followed by upside delivery.
Q1 2026 Context: The Baseline
| Segment | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Total Revenue | USD1.600B | USD0.884B | +85% |
| US Revenue | USD1.282B | USD0.634B | +104% |
| US Commercial | USD0.595B | USD0.255B | +133% |
| US Government | USD0.687B | USD0.373B | +84% |
| Gross Margin | 86.8% | 80.1% | +6.7pp |
| Operating Income | USD0.754B | USD0.161B | +368% |
| Net Income | USD0.871B | USD0.230B | +278% |
| Adj. EPS | USD0.33 | USD0.13 | +154% |
In Q1 2026, Palantir beat the USD0.27 EPS consensus by 22%, extending its streak to eight consecutive beats. Oppenheimer Research anticipates approximately 85% revenue growth in Q2 — above Palantir's own 79% implied guidance — and expects management to raise its full-year outlook.
Full-Year 2026 Guidance (Raised in Q1)
| Metric | FY2026 Guidance | LSEG Street Consensus |
|---|---|---|
| Total Revenue | USD7.65-7.66B | USD7.27B |
| US Commercial Revenue | >USD3.224B (+120%+) | — |
Part B: Three Watch Points for Tonight
1. US Commercial Acceleration: The Central Thesis
The bull case for Palantir rests on a structural shift: from a government-dependent data analytics firm to an AI-powered commercial software platform. In Q1 2026, US commercial revenue grew 133% to USD595M — closing in on US government (USD687M) for the first time.
For Q2, Citi expects US commercial revenue to grow more than 65% YoY. Three sub-metrics to watch:
- Enterprise customer count: In Q1, Palantir held approximately 215 US commercial customers. A jump toward 230-250+ would signal that AIP Bootcamp conversions are accelerating.
- Net new commercial customer adds: The quarterly growth rate is the leading indicator for future revenue.
- Deal size per customer: Has average contract value expanded, or is growth purely driven by customer count?
Palantir's AIP Bootcamp model — in which Palantir engineers embed with enterprise clients for intensive multi-day sessions to build custom AI workflows — is the primary commercial acquisition engine. A Department of the Navy deployment reduced bill of materials approval time from 200 hours to 15 seconds and cut monthly material planning time by 94%. Comparable enterprise case studies in manufacturing, healthcare, and financial services would validate the commercial moat thesis.
2. Guidance Raise: The Inflection Signal
Palantir raised FY2026 revenue guidance to USD7.65-7.66B in Q1 — already 5.3% above the LSEG consensus at the time. Oppenheimer believes management will raise again, potentially above USD8.0B.
| Scenario | Q2 Revenue | FY Guidance | Expected Reaction |
|---|---|---|---|
| Beat + Raise | >USD1.85B | >USD7.8B | +10-15%+ (options: ~12% swing) |
| In-Line + Maintain | USD1.81-1.83B | USD7.65-7.66B | Flat to +3% |
| In-Line, No Raise | ~USD1.80B | Maintained | -5 to -10% |
| Miss | <USD1.79B | Any | -12%+ |
Options markets price approximately a 12% swing in either direction following tonight's report.
3. NHS Controversy: UK Risk or Contained Noise?
On July 29, 2026, NHS England was formally reprimanded by UK data regulators for inaccurately disclosing who could access patient data held on Palantir's Federated Data Platform (FDP). NHS England admitted the disclosure failed to reveal that Palantir staff could directly view identifiable patient records.
The August 2 Financial Times report detailed: "NHS England to revise Palantir platform data after staff concerns." Key context:
- The FDP represents a USD413M (~GBP330M) multi-year contract awarded to Palantir in 2023
- The British Medical Association (BMA) directed doctors in February 2026 to limit engagement with the FDP
- NHS England plans to grant Palantir staff "admin" roles with broad access to identifiable patient data — broader than originally disclosed
- An NHS analytics official received a job-threat warning from a senior administrator after publicly questioning the platform's utility
For investors, two questions management has yet to address:
- Is the GBP330M contract at risk? Not immediately — but renewed public scrutiny increases regulatory pressure and could complicate contract renewal.
- Is this a template for European risk? Stricter GDPR frameworks in other EU markets could face comparable challenges if data access scope is not transparently disclosed.
Valuation Reality Check
| Metric | Value |
|---|---|
| Price (as of Jul 31 close) | USD123.06 |
| Market Capitalization | USD316.4B |
| Forward Revenue Multiple (FY2026) | ~41x |
| Forward P/E (FY2026) | ~138x |
| Analyst Consensus (35 analysts) | Buy (21 Buy / 35 total) |
| Median 12-Month Price Target | USD200 |
| Implied Upside | +63% |
| 2025-2026 Peak Drawdown | -40% |
| Year-to-Date Performance | -30% |
Baird Research rates PLTR a Buy with a USD200 target, designating it the "premier AI growth asset." The bear case centers on rising competition from generalist LLMs commoditizing basic data analytics, and a 138x forward P/E that allows no room for misses.
This earnings preview is based on publicly available analyst estimates and company disclosures. Actual Q2 2026 results will be released tonight after market close. This article is not investment advice.
Sources: Palantir Q1 2026 Business Update (investors.palantir.com); TradingKey PLTR Earnings Preview (August 3, 2026); Blockonomi PLTR Q2 2026 Earnings Preview; MarketBeat PLTR Analyst Forecast; The Register — NHS England rapped over inaccurate Palantir patient data disclosure (July 29, 2026); Financial Times — NHS England to revise Palantir platform data after staff concerns (August 2, 2026); Oppenheimer Research; Citi Research estimates.
